Main Program
We would like to inform you that a Cocktail Viewing will be held at the following location.
Date and time：July 17th (Wed) 17:50-18:50Venue:：Exhibition hall (3F 301+302)
*Food and drink (light meals and alcoholic beverages) will be provided free of charge to conference participants, so please use this as a place to chat before leaving.
Chairman’s Lecture (J)
Date: Jul. 16, 11:20-11:50, Room 1 (501+502)
- Chair
- Yoshikatsu Eto（Advanced Clinical Research Center, Sourthern Tohoku Institute for Neuroscience）
- Performer
- CL. Future direction of JSCGT
- Ryuichi Morishita（Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University）
Presidential Lecture (J)
Chairman’s Lecture
Date: Jul. 17, 14:10-14:40, Room 1 (501+502)
- Chair
- Yoshikazu Yonemitsu（R&D Laboratory for Innovative Biotherapeutics Science, Graduate School of Pharmaceutical Sciences, Kyushu University）
- Performer
- PL. Gene therapy using the migratory activity of neural stem cells
- Masahiro Toda（Department of Neurosurgery, Keio University School of Medicine）
Special Lecture 1 (E)
Date: Jul. 16, 13:10-14:00, Room 1 (501+502)
- Chair
- Tomoki Todo（Division of Innovative Cancer Therapy, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo）
- Performer
- SL1. Neural stem cell delivery of an oncolytic adenovirus in malignant glioma patients
- Maciej S. Lesniak（Department of Neurological Surgery, Northwestern University Feinberg School of Medicine）
Special Lecture 2 (J)
Date: Jul. 17, 14:40-15:30, Room 1 (501+502)
- Chair
- Masafumi Onodera（Gene & Cell Therapy Promotion Center）
- Performer
- SL2. Governmental commitment to create the “Innovation Ecosystem” of gene and cell therapy in Japan
- Toshiharu Furukawa（Members of the House of Councillors, Department of Surgery, Keio University School of Medicine）
Special Lecture 3 (J)
Date: Jul. 18, 12:30-13:20, Room 1 (501+502)
- Chair
- Toya Ohashi（The Jikei University School of Nursing）
- Performer
- SL3. Development of Regenerative Medicine for the CNS Disorders: Challenges Using Genome Editing and Ex vivo Gene Therapy
- Hideyuki Okano（Keio University）
Educational lecture 1 (E)
Date: Jul. 16, 15:50-16:20, Room 1 (501+502)
- Chair
- Masato Yamamoto（Department of Surgery, University of Minnesota）
- Performer
- EL1. Lesson from first clinical trial of oncolytic HSV therapy in recurrent glioblastoma and future development
- Hiroshi Nakashima（Brigham and Women's Hospital, and Harvard Medical School）
Educational lecture 2 (J)
Date: Jul. 17, 17:20-17:50, Room 1 (501+502)
- Chair
- Masahiro Toda（Department of Neurosurgery, Keio University School of Medicine）
- Performer
- EL2. Deep phenotyping of disease and therapeutic cells using AI
- Kazuhiro Sakurada（Keio University School of Medicine）
Educational Lecture 3 (J)
Date: Jul. 18, 10:40-11:10, Room 1 (501+502)
- Chair
- Takafumi Nakamura（Division of genomic Medicine, Tottori University Faculty of Medicine）
- Performer
- EL3. Clinical development of oncolytic herpes viruses
- Tomoki Todo（Division of Innovative Cancer Therapy, and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo）
ASGCT/ESGCT/JSGCT Joint Symposium (E)
Date: Jul. 16, 16:30-18:00, Room 1 (501+502)
- Chairs
- Takafumi Nakamura（Division of genomic Medicine, Tottori University Faculty of Medicine）
- Noriyuki Kasahara（Departments of Neurological Surgery and Radiation Oncology University of California）
- Performer
- JS-1. Recent advances in the treatment of primary immunodeficiencies
- Juan A. Bueren（Director of the Biomedical Innovation Unit. CIEMAT/National Institute for Rare Diseases (CIBERER)）
- JS-2. Lessons Learned from Thirty Years of Clinical AAV Gene Therapy
- Terence R Flotte（Department of Pediatrics, Horae Gene Therapy Center and Microbiology and Physiological Systems (MaPS) University of Massachusetts Chan Medical School）
- JS-3. Recent Progress in Cardiovascular Gene Therapy
- Ryuichi Morishita（Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University）
TAKARA BIO Research Award 2024 (J)
Date: Jul. 17, 13:40-14:00, Room 1 (501+502)
- Chair
- Ryuichi Morishita（Chairman of the Board of Director, The Japan Society of Gene and Cell Therapy / Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University）
- Performer
- Development of brain cell type-specific adeno-associated virus vectors that penetrate the primate blood-brain barrier
- Hirokazu Hirai（Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine / Viral Vector Core, Gunma University Initiative for Advanced Research (GIAR)）
The Japanese Society for Regenerative Medicine Joint Program (J)
Date: Jul. 16, 14:10-15:40, Room 1 (501+502)
- Chairs
- Takashi Okada（Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, IMSUT, The University of Tokyo）
- Masayo Takahashi（VC Cell Therapy Inc., Kobe City Eye Hospital, Ritsumeikan University）
- Performer
- RM-1. Establishing a Consortium for Academia-driven Drug Discovery and Commercialization of Non-viral CAR-T Cells
- Yozo Nakazawa（Department of Pediatrics, Shinshu University School of Medicine）
- RM-2. iPSC-derived next-generation T cell therapy for cervical cancer
- Miki Ando（Department of Hematology, Juntendo University School of Medicine）
- RM-3. Development of the gene replacement therapy for the treatment of spinal muscular atrophy (SMA)
- Toru Hirose（Novartis Pharma KK）
- RM-4. Development of dosing protocol to reduce the required dose of rAAV using mesenchymal stem cells
- Hiromi Hayashita-Kinoh（Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, IMSUT, The University of Tokyo）
- RM-5. Sustanable regenerative medicine
- Masayo Takahashi（VC Cell Therapy Inc., Kobe City Eye Hospital, Ritsumeikan University）
The Japanese Society of Child Neurology Joint Program (J)
Date: Jul. 17, 10:00-11:30, Room 2 (303)
- Chairs
- Hitoshi Osaka（Department of Pediatrics, Jichi Medical University）
- Gaku Yamanaka（Department of Pediatrics and Adolescent Medicine, Tokyo Medical University）
- Performer
- CN-1. New therapeutic management strategies for patients with spinal muscular atrophy
- Tomokazu Kimizu（Osaka Women's and Children's Hospital）
- CN-2. Splice-switching antisense oligonucleotides for treatment of genetic disorders
- Tomonari Awaya（Kyoto University Graduate School of Medicine, Center for Anatomical, Pathological, and Forensic Medical Researches）
- CN-3. Current status of neuronal cell therapy for Dravet syndrome
- Kiyoshi Egawa（Division of Child Maternal and Female medicine, Hokkaido University Hospita）
- CN-4. Gene therapy development for child neurological diseases using AAV vectors
- Karin Kojima（Department of Pediatrics, Jichi Medical University）
The Japanese Society for Genome Editing Joint Program (J)
Date: Jul. 18, 13:30-15:00, Room 1 (501+502)
- Chairs
- Tomoji Mashimo（Division of Animal Genetics, Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo）
- Yumi Kanegae（Jikei University of Medicine）
- Performer
- GE-1. Development of genome-editing treatment for inherited disorders
- Yuji Kashiwakura（Department of Biochemistry, Jichi Medical University）
- GE-2. Development of genome editing tools to introduce disease protective variants
- Atsushi Hoshino（Department of Cardiovascular Medicine Department of Nephrology, Kyoto Prefectural University of Medicine）
- GE-3. Bridge RNAs direct programmable recombination of target and donor DNA
- Masahiro Hiraizumi（Factory of Engineering, The University of Tokyo）
- GE-4. Optical manipulation of the genome
- Moritoshi Sato（Graduate School of Arts and Sciences, The University of Tokyo）
Symposium 1 (J)
Regulatory sciences
Date: Jul. 16, 14:10-15:40, Room 2 (303)
- Chairs
- Akihiro Kume（RPM Co.,Ltd）
- Eriko Uchida（National Institute of Health Sciences）
- Performer
- S1-1. Point-to-Consider for mRNA
- Teruhide Yamaguchi（Nihon Pharmaceutical University）
- S1-2. Point to consider for viral safety strategy of gene therapeutic products in light of ICH Q5AR2
- Akira Sakurai（Pharmaceuticals and Medical devices Agency）
- S1-3. ICH S12 (Nonclinical Biodistribution Considerations for Gene Therapy Products)
- Yuto Takishima（Pharmaceuticals and Medical devices Agency）
- S1-4. PMDA Science Board Subcommittee on Cell and Gene Therapy Products Produced in vivo
- Akihiro Kume（RPM Co.,Ltd）
Symposium 2 (J)
Cancer gene therapy 1
Date: Jul. 16, 16:35-18:05, Room 2 (303)
- Chairs
- Shigeki Yagyu（Shinshu University, Innovative Research & Liaison Organization）
- Kazunori Aoki（National Cancer Center Research Institute）
- Performer
- S2-1. Cell therapy for hematological malignancy - Bench to bedside at National University of Singapore -
- Noriko Shimasaki（Nagoya University Hospital Children's Cancer Center Lecturer of hospital）
- S2-2. CAR-T cell therapy for solid tumors
- Shigeki Yagyu（Shinshu University, Innovative Research & Liaison Organization）
- S2-3. Two New Strategies to Improve the Limitations of Cellular Therapy for Solid Tumors
- Hideki Kasuya（Cancer Immune Therapy Research Center, International Medical Education, Nagoya University, Graduate）
- S2-4. Development of receptor-retargeted oncolytic HSV with syncytial mutations (RRsyn-oHSV)
- Takuma Suzuki（Tokyo University of Pharmacy and Life Sciences）
Symposium 3 (E or J)
Oncolytic virus
Date: Jul. 17, 8:30-10:00, Room 1 (501+502)
- Chairs
- Hiroshi Fukuhara（Urology, Kyorin University）
- Masato Yamamoto（Department of Surgery, University of Minnesota）
- Performer
- S3-1. Reovirus-mediated alteration of tumor microenvironment
- Fuminori Sakurai（Graduate School of Pharmaceutical Sciences, Osaka University）
- S3-2. An investigator-initiated clinical trial of third generation oncolytic virus armed with IL-12 against malignant melanoma
- Ryuhei Okuyama（Department of Dermatology, Shinshu University School of Medicine）
- S3-3. Cretostimogene grenadenorepvec: Pivotal results from CORE-001 and Phase 3 BOND-003 trials for the treatment of high risk, BCG-unresponsive Non-muscle Invasive Blad
- Kasturi Vijay（CG Oncology）
- S3-4. Advancements and Challenges in Oncolytic Virus Therapy: A Clinical Perspective.
- Takashi Kojima（National Cancer Center Hospital East, Gastrointestinal Oncology）
Symposium 4 (E or J)
Vector development
Date: Jul. 17, 10:00-11:30, Room 1 (501+502)
- Chairs
- Hiroyuki Nakai（Oregon Health & Science University）
- Hiroyuki Mizuguchi（Graduate School and School of Pharmaceutical Sciences, Osaka University）
- Performer
- S4-1. Capsid Engineering to Feasibilize Adenoviral Retargeting
- David Curiel（Department of Radiation Oncology, Washington University School of Medicine）
- S4-2. Dawning era of genomic medicines: Strategies for non-viral vectors targeting organs beyond the liver
- Gaurav Sahay（Department of Pharmaceutical Sciences, Oregon State University）
- S4-3. Development of AAV vectors for gene therapy for brain diseases
- Hirokazu Hirai（Gunma University Graduate School of Medicine）
Symposium 5 (J)
Cancer gene therapy 2
Date: Jul. 17, 15:40-17:10, Room 1 (501+502)
- Chairs
- Yozo Nakazawa（Department of Pediatrics, Shinshu University School of Medicine）
- Koji Tamada（Research Institute for Cell Design Medical Science, Yamaguchi University）
- Performer
- S5-1. Real-world experience of CD19 CAR-T cell therapy for ALL in Japan
- Itaru Kato（Kyoto University Hospital）
- S5-2. CAR-T therapy for AML
- Shoji Saito（Shinshu University School of Medicine）
- S5-3. Current status and challenges of CAR-T therapy for hematological malignancies
- Koji Kato（Department of Medicine and Biosystemic Science, Kyushu University, School of Medicine）
- S5-4. Development of new gene-modified cellular immunmotherapy for hematological malignancy
- Naoki Hosen（Department of Hematology and Oncology, Osaka University Graduate School of Medicine）
Symposium 6 (E or J)
Neuromuscular disorders
Date: Jul. 17, 8:30-10:00, Room 2 (303)
- Chairs
- Shin-ichi Muramatsu（Division of Neurological Gene Therapy, Center for Open Innovation, Jichi Medical University）
- Takanori Yamagata（Department of Pediatrics, Tochigi Prefectural Rehabilitation Center）
- Performer
- S6-1. Development of gene therapy for MECP2 gene-related diseases by regulating MECP2 protein expression
- Eriko Jimbo（Department of Pediatrics, Jichi Medical University）
- S6-2. Development of gene therapy for a megalencephalic leukoencephalopathy with subcortical cysts
- Kenji Tanaka（Division of Brain Sciences, Keio University School of Medicine）
- S6-3. Developing NeuroD1 gene therapy to treat neurological disorders
- Gong Chen（Co-Founder, Board Director Chief Scintific Advisor NeuExcell Therapeutics, Director Brain Repair Center Jinan University）
- S6-4. Gene Therapy for Neuromuscular Disorders in Astellas
- Eiji Yoshimi（Astellas Pharma Inc.）
Symposium 7 (J)
Young investigators session
Date: Jul. 17, 16:20-17:50, Room 2 (303)
- Chairs
- Fuminori Sakurai（Graduate School of Pharmaceutical Sciences, Osaka University）
- Kenya Kamimura（Department of General Medicine, Niigata University School of Medicine）
- Performer
- S7-1. Engineering the cancer-targeted oncolytic adenovirus with fiber modification
- Mizuho Sato-Dahlman（Department of Surgery, University of Minnesota, Minneapolis, MN）
- S7-2. Regulation of the immune system by nucleic acid medicine targeting mRNA stem-loop structures
- Osamu Takeuchi（Department of Medical Chemistry, Graduate School of Medicine, Kyoto University）
- S7-3. Development of basic technology for the advancement of mRNA vaccines and viral vector vaccines
- Yasuo Yoshika（Research Institute for Microbial Diseases, Osaka University）
- S7-4. Development of genome editing methods to induce gene therapy via homology directed repair
- Daisuke Matsumoto（Graduate School of Biomedical and Health Sciences, Hiroshima University）
Symposium 8 (J)
Genetic diseases
Date: Jul. 18, 9:00-10:30, Room 1 (501+502)
- Chairs
- Hiroshi Kobayashi（Division of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine）
- Toru Uchiyama（Division of Molecular Pathogenesis, Department of Human Genetics, National Center for Child Health and Development）
- Performer
- S8-1. Hematopoietic stem cell-targeted gene therapy in sickle cell disease
- Naoya Uchida（National Heart, Lung and Blood Institute, National Institutes of Health）
- S8-2. Lentiviral gene therapy targeting hematopoietic stem cells for Pompe disease
- Yota Shimada（Division of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine）
- S8-3. Development of Novel Gene Therapy for Neurological Genetic Disorders
- Kazuhiro Muramatsu（Jichi Medical University）
- S8-4. Advances in Gene Therapy for Inborn Errors of Immunity
- Toru Uchiyama（Division of Molecular Pathogenesis, Department of Human Genetics, National Center for Child Health and Development）
Symposium 9 (E or J)
Regenerative medicine & Cardiovascular diseases
Date: Jul. 18, 9:00-10:30, Room 2 (303)
- Chairs
- Yasuhiro Ikeda（Department of Ophthalmology, Faculty of Medicine, University of Miyazaki）
- Hironori Nakagami（Department of Health Development and Medicine, Graduate school of Medicine, Osaka University）
- Performer
- S9-1. Gene augmentation therapy for inherited retinal dystrophy
- Kazushige Tsunoda（Tokyo Medical Center）
- S9-2. Establishment of visual restoration technology utilizing chimeric rhodopsin
- Toshihide Kurihara（Department of Ophthalmology, Keio University School of Medicine）
- S9-3.
- Seitaro Nomura（Department of Cardiovasculer Medicine, The University of Tokyo Hospital）
- S9-4. Exploring the Mechanism of Therapeutic Effects of Mesenchymal Stem Cells in Ischemic Stroke
- Munehisa Shimamura（Dept. of Gene & Stem Cell Regenerative Therapy, Osaka Univ. Grad. School of Medicine）
- S9-5. Results from clinical trials show evidence of activity for a single intra-myocardial administration of Mesenchymal Precursor Cells in ischemic Heart Failure with reduced Ejection Fraction (HFrEF) patients that also have high inflammation
- Michael Schuster（Mesoblast Inc.）
Plenary Session (E or J)
Date: Jul. 16, 10:10-11:10, Room 1 (501+502)
- Chairs
- Makoto Otsu（Kitasato University School of Allied Health Sciences）
- Katsuto Tamai（Osaka University Graduate School of Medicine）
- Performer
- PS-1. Identification and mechanistic understanding of a novel AAV capsid exhibiting selective and enhanced liver transduction
- Pratheppa Rajagopal（Oregon Health and Science University）
- PS-2. Small-dose in vivo gene therapy for CNS symptoms of lysosomal disease mediated by blood-brain barrier-penetrating enzymes
- Saki Matsushima（The Jikei University School of Medicine）
- PS-3. Restoration of MHC expression by epigenetic modulators facilitates the efficacy of oncolytic virotherapy combined with dendritic cell vaccine in pancreatic cancer
- Kanto Suemori（Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine）
- PS-4. Optimization of Gene Knock-in Technology Targeting the Liver by a Single AAV Vector
- Tomoki Togashi（Kanazawa University）
Panel Discussion (E or J)
Cell therapy
Date: Jul. 16, 10:25-11:10, Room 2 (303)
- Chairs
- Ko Mitani（Saitama Medical University）
- Akinobu Gotoh（Department of Education for Medical Research Base, Hyogo Medical University）
- Performer
- PD-1. Therapeutic Effects of Adipose-Derived Mesenchymal Stem Cells for the Treatment of Patients with Knee Osteoarthritis
- Minseo Kang（College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University）
- PD-2. Generation of natural killer (NK) cells from chimeric antigen receptor (CAR) -transduced human induced pluripotent stem (iPS) cells engineered with NK function-promoting genes for solid cancer therapy
- Masashi Yamada（Healios K.K）
- PD-3. Novel cell therapy CAR-DC suppresses the growth of heterogenous solid tumors through antigen spreading
- Yoshinori Naoe（Nagoya University Graduate School of Medicine, Cancer Immune Therapy Center）